265 related articles for article (PubMed ID: 23364472)
1. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study.
Martins RM; Maia Mde L; Farias RH; Camacho LA; Freire MS; Galler R; Yamamura AM; Almeida LF; Lima SM; Nogueira RM; Sá GR; Hokama DA; de Carvalho R; Freire RA; Pereira Filho E; Leal Mda L; Homma A
Hum Vaccin Immunother; 2013 Apr; 9(4):879-88. PubMed ID: 23364472
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
Juan-Giner A; Kimathi D; Grantz KH; Hamaluba M; Kazooba P; Njuguna P; Fall G; Dia M; Bob NS; Monath TP; Barrett AD; Hombach J; Mulogo EM; Ampeire I; Karanja HK; Nyehangane D; Mwanga-Amumpaire J; Cummings DAT; Bejon P; Warimwe GM; Grais RF
Lancet; 2021 Jan; 397(10269):119-127. PubMed ID: 33422245
[TBL] [Abstract][Full Text] [Related]
3. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine.
Collaborative group for studies on yellow fever vaccines
Vaccine; 2019 Aug; 37(35):5129-5135. PubMed ID: 31171393
[TBL] [Abstract][Full Text] [Related]
4. Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline.
Campi-Azevedo AC; de Almeida Estevam P; Coelho-Dos-Reis JG; Peruhype-Magalhães V; Villela-Rezende G; Quaresma PF; Maia Mde L; Farias RH; Camacho LA; Freire Mda S; Galler R; Yamamura AM; Almeida LF; Lima SM; Nogueira RM; Silva Sá GR; Hokama DA; de Carvalho R; Freire RA; Filho EP; Leal Mda L; Homma A; Teixeira-Carvalho A; Martins RM; Martins-Filho OA
BMC Infect Dis; 2014 Jul; 14():391. PubMed ID: 25022840
[TBL] [Abstract][Full Text] [Related]
5. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.
da Costa-Rocha IA; Machado KLLL; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; de Lima SMB; Miranda EH; Trindade GF; Casagrande TZ; Miyamoto ST; Deotti SC; Barbosa RVR; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Valim V; Martins-Filho OA
Sci Rep; 2021 May; 11(1):10431. PubMed ID: 34001945
[TBL] [Abstract][Full Text] [Related]
6. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial.
Camacho LA; Freire Mda S; Leal Mda L; Aguiar SG; Nascimento JP; Iguchi T; Lozana Jde A; Farias RH;
Rev Saude Publica; 2004 Oct; 38(5):671-8. PubMed ID: 15499438
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Collaborative Group for Studies with Yellow Fever Vaccine
Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases.
Tonacio AC; do Nascimento Pedrosa T; Borba EF; Aikawa NE; Pasoto SG; Filho JCRF; Sampaio Barros MM; Leon EP; Lombardi SCFS; Junior AM; Azevedo AS; Schwarcz WD; Fuller R; Yuki EFN; Ugolini Lopes MR; Rodrigues Pereira RM; Sampaio Barros PD; de Andrade DCO; de Medeiros-Ribeiro AC; de Moraes JCB; Shinjo SK; Miossi R; da Silva Duarte AJ; Lopes MH; Kallás EG; Almeida da Silva CA; Bonfá E
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0010002. PubMed ID: 34843469
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of humoral immune response after yellow fever infection: an observational study on patients from the 2017-2018 sylvatic outbreak in Brazil.
Gonçalves AP; Almeida LT; Rezende IMd; Fradico JRB; Pereira LS; Ramalho DB; Pascoal Xavier MA; Calzavara Silva CE; Monath TP; LaBeaud AD; Drumond BP; Campi-Azevedo AC; Martins-Filho OA; Teixeira-Carvalho A; Alves PA;
Microbiol Spectr; 2024 May; 12(5):e0370323. PubMed ID: 38511952
[TBL] [Abstract][Full Text] [Related]
11. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial.
Camacho LA; de Aguiar SG; Freire Mda S; Leal Mda L; do Nascimento JP; Iguchi T; Lozana JA; Farias RH;
Rev Saude Publica; 2005 Jun; 39(3):413-20. PubMed ID: 15997317
[TBL] [Abstract][Full Text] [Related]
12. Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.
Valim V; Machado KLLL; Miyamoto ST; Pinto AD; Rocha PCM; Serrano EV; Dinis VG; Gouvêa SA; Dias JGF; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; da Costa-Rocha IA; de Lima SMB; Miranda EH; Trindade GF; Maia MLS; Gavi MBRO; da Silva LB; Duque RH; Gianordoli APE; Casagrande TZ; Oliveira KG; Moura BCDM; Nicole-Batista F; Rodrigues LC; Clemente TB; Magalhães ES; Bissoli MF; Gouvea MDPG; Pinto-Neto LFDS; Costa CZ; Giovelli RA; Brandão LR; Polito ETL; Koehlert IO; Borjaille BP; Pereira DB; Dias LH; Merlo DL; Genelhu LFF; Pretti FZ; Giacomin MDS; Burian APN; Fantinato FFST; Pileggi GS; da Mota LMH; Martins-Filho OA
Front Immunol; 2020; 11():1382. PubMed ID: 32765496
[TBL] [Abstract][Full Text] [Related]
13. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak - Final Report.
Casey RM; Harris JB; Ahuka-Mundeke S; Dixon MG; Kizito GM; Nsele PM; Umutesi G; Laven J; Kosoy O; Paluku G; Gueye AS; Hyde TB; Ewetola R; Sheria GKM; Muyembe-Tamfum JJ; Staples JE
N Engl J Med; 2019 Aug; 381(5):444-454. PubMed ID: 29443626
[TBL] [Abstract][Full Text] [Related]
15. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
Casagrande TZ; Costa-Rocha IAD; Gavi MBRO; Miyamoto ST; Martins PC; Serrano ÉV; Dinis VG; Machado KLLL; Gouvea SA; Caser LC; Campi-Azevedo AC; Teixeira-Carvalho A; Peruhype-Magalhães V; Bissoli MF; Gouvea MDPG; Lima SMB; Miranda EH; Trindade GF; Lyra DGP; Burian APN; Neto LFDSP; da Mota LMH; Martins-Filho OA; Valim V
Vaccine; 2022 Jul; 40(32):4580-4593. PubMed ID: 35728990
[TBL] [Abstract][Full Text] [Related]
16. Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.
Ferreira CC; Campi-Azevedo AC; Peruhype-Magalhāes V; Coelho-Dos-Reis JG; Antonelli LRDV; Torres K; Freire LC; da Costa-Rocha IA; Oliveira ACV; Maia MLS; de Lima SMB; Domingues CM; Teixeira-Carvalho A; Martins-Filho OA; da Mota LMH;
Arthritis Res Ther; 2019 Mar; 21(1):75. PubMed ID: 30871593
[TBL] [Abstract][Full Text] [Related]
17. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
[TBL] [Abstract][Full Text] [Related]
18. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old.
Collaborative Group for Studies of Yellow Fever Vaccine
Mem Inst Oswaldo Cruz; 2015 Sep; 110(6):771-80. PubMed ID: 26517656
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
[TBL] [Abstract][Full Text] [Related]
20. Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.
da Costa-Rocha IA; Campi-Azevedo AC; Peruhype-Magalhães V; Coelho-Dos-Reis JG; Fradico JRB; Souza-Lopes T; Reis LR; Freire LC; Costa-Pereira C; Mambrini JVM; Maia MLS; de Lima SMB; de Noronha TG; Xavier JR; Camacho LAB; de Albuquerque EM; Farias RHG; de Castro TDM; Homma A; Romano APM; Domingues CM; Martins RM; Teixeira-Carvalho A; Martins-Filho OA
Front Immunol; 2019; 10():1211. PubMed ID: 31293563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
